Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Share-based Compensation came in at -$17.4 million in Q3 2025, down 297.4% YoY from $8.8 million in Q3 2024, and down 303.76% on a QoQ basis from $8.5 million in Q2 2025.
Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Share-based Compensation data on file, last reported at -$17.4 million in Q3 2025.
- Quarterly Share-based Compensation fell 297.4% year-over-year to -$17.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $9.2 million (down 64.16% YoY) and the FY2024 annual result came in at $34.9 million, up 2506.28% from the prior year.
- Share-based Compensation slipped to -$17.4 million in Q3 2025, from $8.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $15.4 million in Q4 2022 to a low of -$17.4 million in Q3 2025.
- A 5-year average of $4.2 million and a median of $8.1 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation jumped 20683.33% — and 2025, when it plunged 297.4%.
- Tracing KROS's Share-based Compensation over 5 years: stood at $3.3 million in 2021, then soared by 368.07% to $15.4 million in 2022, then plunged by 173.85% to -$11.4 million in 2023, then surged by 180.77% to $9.2 million in 2024, then sank by 289.18% to -$17.4 million in 2025.
- The last three Share-based Compensation figures came in at -$17.4 million (Q3 2025), $8.5 million (Q2 2025), and $8.9 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.31 Mn |
| Dec 31, 2025 | 7.31 Mn |
| Sep 30, 2025 | -17.41 Mn |
| Sep 30, 2025 | -17.41 Mn |
| Jun 30, 2025 | 8.54 Mn |
| Jun 30, 2025 | 8.54 Mn |
| Mar 31, 2025 | 8.86 Mn |
| Mar 31, 2025 | 8.86 Mn |
| Dec 31, 2024 | 9.20 Mn |
| Dec 31, 2024 | 9.20 Mn |
| Sep 30, 2024 | 8.82 Mn |
| Sep 30, 2024 | 8.82 Mn |
| Jun 30, 2024 | 8.79 Mn |
| Jun 30, 2024 | 8.79 Mn |
| Mar 31, 2024 | 8.07 Mn |
| Mar 31, 2024 | 8.07 Mn |
| Sep 30, 2023 | -11.39 Mn |
| Sep 30, 2023 | -11.39 Mn |
| Jun 30, 2023 | 11.39 Mn |
| Jun 30, 2023 | 11.39 Mn |